IRCT20210625051698N1Not yet recruiting未知
The evaluation of effects of Daflon tablet on symptoms of hemorrhoids, its relapse and patients' duration of hospitalization
Karaj University of Medical Sciences0 sites200 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Patients over the age of 18 years old who were diagnosed with grade 3 or 4 of hemorrhoids based on a surgeons' physical exam and history taking
Exclusion Criteria
- •Does not have a history of previous treatment of hemorrhoids.
- •Does not have a history of consumption or allergy to Daflon tablet.
- •Does not have a history of renal failure or electrolytes imbalance.
- •Does not have a serious underlying disease, including immunodeficiency disease, hyperparathyroidism, complete heart block, addison's disease, intestinal disorders, or malignancies.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
Active, not recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
Active, not recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
Active, not recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500
Completed
Phase 3
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330